<rss version="2.0">
<channel>
<title>IBTimes.com RSS Feed - Pfizer</title>
<description>International Business News - Pfizer</description>
<link>http://www.ibtimes.com</link>
<copyright>All articles are copyrighted by IBTimes.com</copyright>

<image>
	<title>The International Business Times - Business News, Updated daily</title> 
	<width>400</width> 
	<height>100</height> 
	<link>http://www.ibtimes.com/</link> 
	<url>http://www.ibtimes.com/images/top_logo_ibt2_3.gif</url> 
</image>


  <item>
  <title>Pfizer continues realigning with 3 new units</title>
  <description>Pfizer Inc., continuing its drive to create more focused business units, told employees worldwide Tuesday it is replacing its current geographic divisions with new ones centered on primary care, specialty care and operations in emerging markets.</description>
    <link>http://www.ibtimes.com/articles/20081007/pfizer-continues-realigning-with-3-new-units.htm</link> 
  <pubDate>Tue, 07 Oct 2008 11:33:15 EDT</pubDate>
  </item>


  <item>
  <title>Pfizer shifts focus to cancer and biotech drugs</title>
  <description>Pfizer Inc. is shifting its research focus to diseases that have high potential for big profits and for treatment improvements, such as cancer and Alzheimer's disease.</description>
    <image>
  <url>http://www.ibtimes.com/data/articleimgs/142768-pfizer-pipeline-shift.jpg</url>
  <link>http://www.ibtimes.com/articles/20080930/pfizer-shifts-focus-to-cancer-and-biotech-drugs.htm</link>
  </image>
    <link>http://www.ibtimes.com/articles/20080930/pfizer-shifts-focus-to-cancer-and-biotech-drugs.htm</link> 
  <pubDate>Tue, 30 Sep 2008 17:37:24 EDT</pubDate>
  </item>


  <item>
  <title>Ahead of the Bell: Pfizer</title>
  <description>Drug maker Pfizer Inc. is reportedly planning to stop developing drugs for heart disease, obesity and bone health to focus on more profitable fields such as treatments for cancer and Alzheimer's disease.</description>
    <link>http://www.ibtimes.com/articles/20080930/ahead-of-the-bell-pfizer.htm</link> 
  <pubDate>Tue, 30 Sep 2008 08:25:48 EDT</pubDate>
  </item>


  <item>
  <title>Pfizer, Nobel winner team up on health program</title>
  <description>Drugmaker Pfizer Inc. is working with the founder of Nobel Peace Prize-winning Bangladeshi microlender Grameen Bank to improve health care delivery--and eventually boost sales of its drugs--in poor countries.</description>
    <link>http://www.ibtimes.com/articles/20080924/pfizer-nobel-winner-team-up-on-health-program.htm</link> 
  <pubDate>Wed, 24 Sep 2008 15:59:04 EDT</pubDate>
  </item>


  <item>
  <title>Pfizer retooling, pushing emerging market sales</title>
  <description>Pfizer Inc. is dramatically stepping up sales efforts in emerging markets, overhauling U.S. business operations and slashing more costs ahead of the 2011 patent loss for cholesterol blockbuster Lipitor, its head of pharmaceutical operations said Monday.</description>
    <link>http://www.ibtimes.com/articles/20080922/pfizer-retooling-pushing-emerging-market-sales.htm</link> 
  <pubDate>Mon, 22 Sep 2008 16:54:35 EDT</pubDate>
  </item>


  <item>
  <title>Pfizer switching Exubera patients to MannKind drug</title>
  <description>Pfizer Inc. will start switching Exubera inhaled insulin patients to MannKind Corp.'s experimental Technosphere product, which just completed late-stage development.</description>
    <link>http://www.ibtimes.com/articles/20080916/pfizer-switching-exubera-patients-to-mannkind-drug.htm</link> 
  <pubDate>Tue, 16 Sep 2008 09:37:45 EDT</pubDate>
  </item>


  <item>
  <title>Pfizer launches site weighing drug risks, benefits</title>
  <description>Amid the deluge of drug advertising and news about safety issues, plenty of patients are bewildered over how to weigh the risks and benefits of a medication, or even how to find out what they are.</description>
    <image>
  <url>http://www.ibtimes.com/data/articleimgs/130750-pfizer.jpg</url>
  <link>http://www.ibtimes.com/articles/20080915/pfizer-launches-site-weighing-drug-risks-benefits.htm</link>
  </image>
    <link>http://www.ibtimes.com/articles/20080915/pfizer-launches-site-weighing-drug-risks-benefits.htm</link> 
  <pubDate>Mon, 15 Sep 2008 10:54:43 EDT</pubDate>
  </item>


  <item>
  <title>Pfizer takes more time with antibiotic application</title>
  <description>Pfizer Inc. said Tuesday it will withdraw approval requests for the antibiotic dalbavancin and conduct another late-stage clinical trial before reapplying.</description>
    <link>http://www.ibtimes.com/articles/20080909/pfizer-takes-more-time-with-antibiotic-application.htm</link> 
  <pubDate>Tue, 09 Sep 2008 12:40:51 EDT</pubDate>
  </item>


  <item>
  <title>Panel cites benefits of Pfizer osteoporosis drug</title>
  <description>An experimental drug from Pfizer could benefit certain women with osteoporosis, federal advisers said Monday, despite concerns of side effects. A Food and Drug Administration panel of experts voted 9-3 that the benefits of Fablyn could outweigh its risks, including blood clots and vaginal bleeding, for some women. The FDA is not required to follow the advice of its advisers, though it often does.</description>
    <link>http://www.ibtimes.com/articles/20080908/panel-cites-benefits-of-pfizer-osteoporosis-drug.htm</link> 
  <pubDate>Mon, 08 Sep 2008 16:13:33 EDT</pubDate>
  </item>


  <item>
  <title>Medarex gets milestone payment from Pfizer</title>
  <description>Medarex Inc. said Monday it received a milestone payment after Pfizer Inc. planned to begin clinical trials of a product Pfizer developed using Madera's ultimo technology.</description>
    <link>http://www.ibtimes.com/articles/20080908/medarex-gets-milestone-payment-from-pfizer.htm</link> 
  <pubDate>Mon, 08 Sep 2008 12:21:23 EDT</pubDate>
  </item>


  <item>
  <title>FDA wary of deaths with Pfizer osteoporosis drug</title>
  <description>Federal regulators say a drug from Pfizer and Ligand Pharmaceuticals effectively treats osteoporosis, though they are concerned about deaths, blood clots and other problems seen in company studies.</description>
    <link>http://www.ibtimes.com/articles/20080904/fda-wary-of-deaths-with-pfizer-osteoporosis-drug.htm</link> 
  <pubDate>Thu, 04 Sep 2008 16:55:49 EDT</pubDate>
  </item>


  <item>
  <title>Pfizer and Medivation to partner on Dimebon</title>
  <description>Pfizer Inc. and Medivation Inc. on Wednesday entered a partnership to develop and promote Medivation's Dimebon, a drug candidate designed to treat Alzheimer's disease and Huntington's disease.</description>
    <link>http://www.ibtimes.com/articles/20080903/pfizer-and-medivation-to-partner-on-dimebon.htm</link> 
  <pubDate>Wed, 03 Sep 2008 08:55:18 EDT</pubDate>
  </item>


  <item>
  <title>Study: Pfizer, Bristol-Myers drug boosts bleeding</title>
  <description>Pfizer Inc. and Bristol-Myers Squibb Co. said Tuesday a midstage safety study showed their experimental blood thinner apixaban did increase patients' risk of bleeding, but may also reduce patients' risk of a second heart attack, stroke or death.</description>
    <link>http://www.ibtimes.com/articles/20080902/study-pfizer-bristol-myers-drug-boosts-bleeding.htm</link> 
  <pubDate>Tue, 02 Sep 2008 16:33:17 EDT</pubDate>
  </item>


  <item>
  <title>Pfizer wins patent dispute over Lipitor in Denmark</title>
  <description>Pfizer Inc. said Friday a court in Denmark has blocked Ranbaxy Laboratories from launching a generic version of the blockbuster cholesterol drug Lipitor in that country.</description>
    <link>http://www.ibtimes.com/articles/20080829/pfizer-wins-patent-dispute-over-lipitor-in-denmark.htm</link> 
  <pubDate>Fri, 29 Aug 2008 09:58:04 EDT</pubDate>
  </item>


  <item>
  <title>Schering-Plough: EU OKs product sale to Pfizer</title>
  <description>U.S. drug maker Schering-Plough Corp. won EU approval Wednesday to sell off several animal vaccines and medicines to rival Pfizer Corp., obeying an earlier EU antitrust order to offload some assets before it could buy another pharmaceutical business.</description>
    <link>http://www.ibtimes.com/articles/20080827/schering-plough-eu-oks-product-sale-to-pfizer.htm</link> 
  <pubDate>Wed, 27 Aug 2008 11:45:04 EDT</pubDate>
  </item>


  <item>
  <title>New type of anti-clotting drug misses testing goal</title>
  <description>A new type of blood thinner being developed by two top pharmaceutical companies didn't meet its goal in a late-stage test of its ability to prevent certain dangerous blood clots, but research for other uses will continue, the companies said late Tuesday.</description>
    <link>http://www.ibtimes.com/articles/20080826/new-type-of-anti-clotting-drug-misses-testing-goal.htm</link> 
  <pubDate>Tue, 26 Aug 2008 18:03:45 EDT</pubDate>
  </item>


  <item>
  <title>Pfizer biotech unit plans San Francisco relocation</title>
  <description>San Francisco Mayor Gavin Newsom has announced that Pfizer Inc. will relocate its biotech research center to the city, a move leaders hope will attract other biomedical businesses.</description>
    <link>http://www.ibtimes.com/articles/20080806/pfizer-biotech-unit-plans-san-francisco-relocation.htm</link> 
  <pubDate>Wed, 06 Aug 2008 15:58:46 EDT</pubDate>
  </item>


  <item>
  <title>FDA schedules meeting on drug from Pfizer, Ligand</title>
  <description>Federal medical advisers will meet next month to review an experimental drug to treat osteoporosis from Pfizer Inc. and Ligand Pharmaceuticals Inc. The Food and Drug Administration said Wednesday its panel of reproductive drug experts will meet Sept. 8 to consider the drug Fablyn, which regulates the hormone estrogen. New York-based Pfizer, the world's largest drugmaker, developed Fablyn with partner Ligand Pharmaceuticals.</description>
    <link>http://www.ibtimes.com/articles/20080806/fda-schedules-meeting-on-drug-from-pfizer-ligand.htm</link> 
  <pubDate>Wed, 06 Aug 2008 12:11:46 EDT</pubDate>
  </item>


  <item>
  <title>Pfizer spent nearly $3.1 million lobbying in 2Q</title>
  <description>Pfizer Inc., the world's largest drugmaker, spent nearly $3.1 million lobbying the federal government in the second quarter, according to a recent disclosure form.</description>
    <link>http://www.ibtimes.com/articles/20080805/pfizer-spent-nearly-3-1-million-lobbying-in-2q.htm</link> 
  <pubDate>Tue, 05 Aug 2008 11:24:56 EDT</pubDate>
  </item>


  <item>
  <title>Earnings roundup: Pfizer, General Dynamics</title>
  <description>Among the earnings stories for Wednesday, July 23, from AP Financial News: Top stories:</description>
    <link>http://www.ibtimes.com/articles/20080723/earnings-roundup-pfizer-general-dynamics.htm</link> 
  <pubDate>Wed, 23 Jul 2008 10:39:45 EDT</pubDate>
  </item>


</channel>
</rss>